US 11,680,267 B2
Co-regulatory sequences based on tetracycline and Cumate
Bofu Xue, Guangdong (CN); Yinhui Yang, Guangdong (CN); Ke Liu, Guangdong (CN); and Mo Ma, Guangdong (CN)
Assigned to Shenzhen Eureka Biotechnology Co., Ltd., Guangdong (CN)
Appl. No. 17/766,685
Filed by Shenzhen Eureka Biotechnology Co., Ltd., Guandong (CN)
PCT Filed Sep. 16, 2020, PCT No. PCT/CN2020/115520
§ 371(c)(1), (2) Date Apr. 5, 2022,
PCT Pub. No. WO2021/232632, PCT Pub. Date Nov. 25, 2021.
Claims priority of application No. 202010442506.3 (CN), filed on May 22, 2020.
Prior Publication US 2022/0364103 A1, Nov. 17, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/63 (2006.01); C12N 15/85 (2006.01)
CPC C12N 15/635 (2013.01) [C12N 15/85 (2013.01); C12N 2800/10 (2013.01); C12N 2800/22 (2013.01); C12N 2830/001 (2013.01); C12N 2830/003 (2013.01)] 20 Claims
 
1. A nucleic acid sequence, comprising at least 2 copies of Tet operator (TetO) sequences capable of binding to a reverse tetracycline controlled transactivator (rtTA) regulatable by tetracycline or a derivative thereof, 1 copy of a minimal promoter sequence containing a TATA box sequence, and at least 1 copy of a Cumate operator (CuO) sequence capable of binding to a transcription repressor cysteine metabolism repressor (CymR) regulatable by cumate, wherein the CuO-sequence is downstream of the 3′ end of the TATA box sequence, and is 30 bp to 50 bp apart from the TATA box.